Published • loading... • Updated
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
- Akeso, Inc. reported record-high drug sales revenue of approximately RMB 1,803.2 million in the first half of 2026, a 28.7% increase year-over-year.
- By the end of 2025, Akeso's five self-commercialized innovative drugs covering 12 indications were included in China's National Reimbursement Drug List .
- In August 2026, China's National Medical Products Administration approved ivonescimab combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer.
- Akeso is advancing its IO2.0+ global strategy focused on bispecific antibody therapies and next-generation antibody-drug conjugates, including clinical-stage compounds AK146D1 and AK138D1, which have entered clinical development.
Insights by Ground AI
46 Articles
46 Articles
The Logan Banner+45 Reposted by 45 other sources
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built…
Coverage Details
Total News Sources46
Leaning Left6Leaning Right2Center30Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
L 16%
C 79%
Factuality
To view factuality data please Upgrade to Premium
